|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
123,030,000 |
Market
Cap: |
17.71(B) |
Last
Volume: |
477,045 |
Avg
Vol: |
726,924 |
52
Week Range: |
$143.71 - $212.05 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 824 |
Guru Rank Value : 0.5 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
46,855 |
76,855 |
102,504 |
247,093 |
Total Sell Value |
$7,107,715 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
Total People Sold |
6 |
7 |
8 |
9 |
Total Sell Transactions |
11 |
12 |
18 |
35 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Maraganore John |
Chief Executive Officer |
|
2021-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
14,167 |
234,299 |
|
- |
|
Greenstreet Yvonne |
President & COO |
|
2021-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,417 |
16,440 |
|
- |
|
Maraganore John |
Chief Executive Officer |
|
2021-12-10 |
4 |
OE |
$42.22 |
$399,829 |
D/D |
5,367 |
220,132 |
|
- |
|
Maraganore John |
Chief Executive Officer |
|
2021-11-12 |
4 |
AS |
$170.36 |
$5,827,801 |
D/D |
(33,978) |
214,765 |
|
-5% |
|
Maraganore John |
Chief Executive Officer |
|
2021-11-12 |
4 |
OE |
$7.10 |
$241,244 |
D/D |
33,978 |
248,743 |
|
- |
|
Maraganore John |
Chief Executive Officer |
|
2021-08-13 |
4 |
AS |
$198.02 |
$6,788,196 |
D/D |
(33,979) |
214,765 |
|
-1% |
|
Maraganore John |
Chief Executive Officer |
|
2021-08-13 |
4 |
OE |
$7.10 |
$241,251 |
D/D |
33,979 |
248,744 |
|
- |
|
Vaishnaw Akshay |
President, R&D |
|
2021-08-09 |
4 |
AS |
$200.00 |
$2,166,800 |
D/D |
(10,834) |
11,215 |
|
-8% |
|
Vaishnaw Akshay |
President, R&D |
|
2021-08-09 |
4 |
OE |
$63.00 |
$682,542 |
D/D |
10,834 |
22,049 |
|
- |
|
Greenstreet Yvonne |
President & COO |
|
2021-08-06 |
4 |
AS |
$199.00 |
$10,559,736 |
D/D |
(53,064) |
11,023 |
|
-2% |
|
Greenstreet Yvonne |
President & COO |
|
2021-08-06 |
4 |
OE |
$77.10 |
$4,091,234 |
D/D |
53,064 |
64,087 |
|
- |
|
Keating Laurie |
EVP, Chief Legal Officer |
|
2021-08-05 |
4 |
AS |
$188.95 |
$1,889,500 |
D/D |
(10,000) |
5,132 |
|
-4% |
|
Keating Laurie |
EVP, Chief Legal Officer |
|
2021-08-05 |
4 |
OE |
$88.95 |
$889,500 |
D/D |
10,000 |
15,132 |
|
- |
|
Keating Laurie |
EVP, Chief Legal Officer |
|
2021-07-12 |
4 |
AS |
$178.95 |
$1,219,098 |
D/D |
(6,812) |
5,132 |
|
-2% |
|
Keating Laurie |
EVP, Chief Legal Officer |
|
2021-07-12 |
4 |
OE |
$85.00 |
$598,770 |
D/D |
6,812 |
11,944 |
|
- |
|
Vaishnaw Akshay |
President, R&D |
|
2021-06-18 |
4 |
AS |
$175.00 |
$2,573,900 |
D/D |
(14,708) |
11,215 |
|
12% |
|
Vaishnaw Akshay |
President, R&D |
|
2021-06-18 |
4 |
OE |
$42.22 |
$723,495 |
D/D |
11,804 |
25,923 |
|
- |
|
Keating Laurie |
EVP, Chief Legal Officer |
|
2021-06-09 |
4 |
AS |
$154.00 |
$267,036 |
D/D |
(1,734) |
5,132 |
|
32% |
|
Maraganore John |
Chief Executive Officer |
|
2021-05-13 |
4 |
AS |
$128.30 |
$4,443,725 |
D/D |
(33,979) |
214,765 |
|
37% |
|
Maraganore John |
Chief Executive Officer |
|
2021-05-13 |
4 |
OE |
$7.10 |
$241,251 |
D/D |
33,979 |
248,744 |
|
- |
|
Vaishnaw Akshay |
President, R&D |
|
2021-04-21 |
4 |
AS |
$135.41 |
$374,135 |
D/D |
(2,732) |
14,119 |
|
48% |
|
Vaishnaw Akshay |
President, R&D |
|
2021-04-20 |
4 |
D |
$131.75 |
$309,983 |
D/D |
(2,351) |
16,851 |
|
- |
|
Poulton Jeffrey V. |
Chief Financial Officer |
|
2021-04-20 |
4 |
D |
$131.75 |
$182,347 |
D/D |
(1,383) |
3,135 |
|
- |
|
Greenstreet Yvonne |
President & COO |
|
2021-04-20 |
4 |
D |
$131.75 |
$309,977 |
D/D |
(2,351) |
11,023 |
|
- |
|
Keating Laurie |
EVP, Chief Legal Officer |
|
2021-04-20 |
4 |
D |
$131.75 |
$275,426 |
D/D |
(2,089) |
6,866 |
|
- |
|
475 Records found
|
|
Page 5 of 19 |
|
|